The FDA has issued Sobi, also known as Swedish Orphan Biovitrum, a complete response letter for its combination gout treatment over production concerns and issues with its third-party manufacturing sites.
The FDA has issued Sobi, also known as Swedish Orphan Biovitrum, a complete response letter for its combination gout treatment over production concerns and issues …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
FDA rejects Sobi’s gout drug over manufacturing issues, sparing Amgen blockbuster
Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
FDA slaps Dr. Reddy's Hyderabad biologics plant with seven observations in new Form 483
Unicycive turned away by FDA again over manufacturer’s plant shortfalls
Sobi’s plan to introduce a challenger to Amgen’s blockbuster gout drug Krystexxa has been put on hold by the FDA. | Sobi’s plan…
GSK and Spero Therapeutics have scor | Four years after Spero Therapeutics received a complete response letter from the FDA,…
Unicycive's CKD drug oxylanthanum carbonate gets a second FDA rejection over third-party manufacturing issues; shares drop ~50%…
The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading…
FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late 2026. See market reaction.
GSK’s recent deal to license out a rare liver disease drug just got sweeter.
